ClinicalTrials.gg

Program

nbm-t-bmx-os 01

Its studies are mostly in Brain Neoplasms · Neoplasms, led by Novelwise Pharmaceutical.

Furthest: phase 2, since Aug 11, 20232 company-led studies, 2 open or runningNext primary completion: May 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novelwise Pharmaceutical22 open or runningphase 2since Aug 11, 2023Aug 11, 2023May 30, 2028phase 2 · NCT06012695

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2023First study: phase 2 study in NeoplasmsFirst studyNCT06012695 · 79 planned · Taiwan
  2. Apr 24, 2026Phase 2 study in Brain NeoplasmsNCT07569042 · 15 planned · Taiwan

Ahead

  1. May 30, 2028Primary completion: phase 2 study in NeoplasmsNCT06012695
  2. Sep 30, 2029Primary completion: phase 2 study in Brain NeoplasmsNCT07569042

TargetBeta

HDAC8 →read by rule
“An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), ”NCIt, by rule

Other programs on HDAC8

ProgramCompanyFurthest phaseStudies
givinostatruleItalfarmacophase 323
givinostat hydrochlorideruleItalfarmacophase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07569042Brain Neoplasms · Taiwan2RecruitingSep 30, 202915
NCT06012695Neoplasms · Taiwan2RecruitingMay 30, 202879

How it is read

Names in the registry

  • “NBM-BMX Capsule”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.